ClinicalTrials.gg

Program

valbenazine

Also written as “Valbenazine”, “NBI-98854” and “MT-5199”.

Its studies are mostly in Tardive Dyskinesia · Tourette Syndrome · Schizophrenia · Huntington Disease · Dyskinesias, led by 2 companies.

Furthest: phase 4, since Oct 4, 201828 company-led studies, 2 open or runningNext primary completion: Apr 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Neurocrine Biosciences272 open or runningphase 4since Oct 4, 2018Dec 21, 2010Apr 2028phase 3 · NCT06312189
Tanabe Pharma10 open or runningphase 3since Jun 2, 2017Jun 2, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 15 studies since Dec 21, 2010.

  1. Feb 19, 2018Phase 2 study in Tourette SyndromeNeurocrine Biosciences · NCT03444038 · 85 enrolled · United States, Puerto Rico
  2. May 8, 2018Phase 2 study in Tourette SyndromeNeurocrine Biosciences · NCT03530293 · 81 enrolled · United States, Puerto Rico
  3. Oct 4, 2018Phase 4 study in Tardive DyskinesiaNeurocrine Biosciences · NCT03698331 · 89 enrolled · United States, Puerto Rico
  4. Nov 5, 2018Phase 2 study in Tourette SyndromeNeurocrine Biosciences · NCT03732534 · 6 enrolled · United States, Puerto Rico
  5. Mar 25, 2019Phase 4 study in Tardive DyskinesiaNeurocrine Biosciences · NCT03891862 · 135 enrolled · United States, Puerto Rico
  6. Sep 23, 2019Phase 3 study in Huntington DiseaseNeurocrine Biosciences · NCT04102579 · 128 enrolled · United States, Canada
  7. May 19, 2020Phase 3 study in Huntington DiseaseNeurocrine Biosciences · NCT04400331 · 154 enrolled · United States, Canada
  8. Oct 26, 2021Phase 3 study in SchizophreniaNeurocrine Biosciences · NCT05110157 · 442 enrolled · United States, Argentina, Bulgaria and more
  9. Jan 10, 2022Phase 3 study in DyskinesiasNeurocrine Biosciences · NCT05206513 · 86 enrolled · United States, Argentina, Belgium and more
  10. Dec 8, 2022Phase 3 study in SchizophreniaNeurocrine Biosciences · NCT05654870 · 8 enrolled · United States
  11. May 5, 2023Phase 4 study in SchizophreniaNeurocrine Biosciences · NCT05859698 · 59 enrolled · United States
  12. Mar 8, 2024Phase 3 study in Huntington DiseaseNeurocrine Biosciences · NCT06312189 · 7 planned · Canada
  13. Jul 29, 2025Phase 4 study in SchizophreniaNeurocrine Biosciences · NCT07105111 · 100 planned · United States
  14. Nov 3, 2026Phase 3 study terminatedStudy stoppedNCT04400331 · “Sponsor Decision”

Ahead

  1. Apr 2028Primary completion: phase 3 study in Huntington DiseaseNeurocrine Biosciences · NCT06312189
  2. Jun 2028Primary completion: phase 4 study in SchizophreniaNeurocrine Biosciences · NCT07105111

TargetBeta

SLC18A2 →read by rule
“Synaptic vesicular amine transporter inhibitor; Synaptic vesicular amine transporter inhibitor”ChEMBL 37, by rule

Other programs on SLC18A2

ProgramCompanyFurthest phaseStudies
lisdexamfetamineruleTakedaphase 447
deutetrabenazineruleTeva Pharmaceutical Industriesphase 412

Studies

All 28 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07105111Schizophrenia · United States4RecruitingNeurocrine BiosciencesJun 2028100
NCT06312189Huntington Disease · Canada3By invitationNeurocrine BiosciencesApr 20287
NCT05859698Schizophrenia · United States4CompletedNeurocrine BiosciencesDec 27, 202459
NCT05654870Schizophrenia · United States3TerminatedNeurocrine BiosciencesNov 8, 20238
NCT05206513Dyskinesias · United States, Argentina, Belgium and more3CompletedNeurocrine BiosciencesOct 16, 202586
NCT05110157Schizophrenia · United States, Argentina, Bulgaria and more3CompletedNeurocrine BiosciencesFeb 4, 2025442
NCT04400331Huntington Disease · United States, Canada3TerminatedNeurocrine BiosciencesNov 5, 2025154
NCT04102579Huntington Disease · United States, Canada3CompletedNeurocrine BiosciencesOct 15, 2021128
NCT03891862Tardive Dyskinesia · United States, Puerto Rico4CompletedNeurocrine BiosciencesDec 23, 2019135
NCT03732534Tourette Syndrome · United States, Puerto Rico2TerminatedNeurocrine BiosciencesFeb 18, 20196
NCT03698331Tardive Dyskinesia · United States, Puerto Rico4CompletedNeurocrine BiosciencesApr 3, 201989
NCT03530293Tourette Syndrome · United States, Puerto Rico2TerminatedNeurocrine BiosciencesJul 16, 201981
NCT03444038Tourette Syndrome · United States, Puerto Rico2CompletedNeurocrine BiosciencesJul 12, 201985
NCT03325010Tourette Syndrome · United States, Puerto Rico2CompletedNeurocrine BiosciencesNov 1, 2018127
NCT03176771Tardive Dyskinesia · Japan3CompletedTanabe PharmaSep 29, 2020256
NCT02879578Tourette Syndrome · United States2CompletedNeurocrine BiosciencesNov 1, 2017155
NCT02736955Tardive Dyskinesia · United States3CompletedNeurocrine BiosciencesJun 30, 2017161
NCT02679079Tourette Syndrome · United States2CompletedNeurocrine BiosciencesApr 14, 201798
NCT02581865Tourette Syndrome · United States2CompletedNeurocrine BiosciencesDec 2016124
NCT02405091Tardive Dyskinesia · United States, Canada, Puerto Rico3CompletedNeurocrine BiosciencesMar 2017167
NCT02274558Tardive Dyskinesia · United States, Canada, Puerto Rico3CompletedNeurocrine BiosciencesSep 2015234
NCT02256475Tourette Syndrome · United States1CompletedNeurocrine BiosciencesNov 201536
NCT01916993Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects · United States1CompletedNeurocrine BiosciencesDec 201324
NCT01910480Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects · United States1CompletedNeurocrine BiosciencesAug 201324
NCT01733121Tardive Dyskinesia · United States, Puerto Rico2CompletedNeurocrine BiosciencesDec 2013102
NCT01688037Tardive Dyskinesia · United States, Puerto Rico2CompletedNeurocrine BiosciencesSep 2013109
NCT01393600Tardive Dyskinesia · United States2CompletedNeurocrine BiosciencesFeb 201237
NCT01267188Tardive Dyskinesia · Canada2CompletedNeurocrine BiosciencesMar 201110

How it is read

Names in the registry

  • “Valbenazine”, 15 entries
  • “NBI-98854”, 13 entries
  • “MT-5199”, 1 entry
  • “NBI-98854 50 mg capsule”, 1 entry
  • “NBI-98854 50 mg capsule once daily”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
valbenazine (Neurocrine Biosciences): development program | ClinicalTrials.gg